A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-313)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511599-33-00

Acronym

LOXO-BTK-20023

Enrollment

166

Registered

2024-05-28

Start date

2021-12-22

Completion date

Unknown

Last updated

2025-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Brief summary

Assessed by IRC: PFS per iwCLL 2018 response criteria

Interventions

DRUGBENDAMUSTINE

DRUGRITUXIMAB

DRUGPIRTOBRUTINIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Assessed by IRC: PFS per iwCLL 2018 response criteria	—

Countries

Austria, Bulgaria, Czechia, France, Hungary, Italy, Poland, Portugal, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026